HomesToLife Ltd Announces Acquisition of HTL Marketing Pte Ltd, with 2024 Sales of US$330 Million

HomesToLife Ltd (HTLM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 HomesToLife Reports 10% YoY Growth in 1H 2026 Net Revenue, Fuelled by Stronger Export Sales SINGAPORE, Sept 30, 2026 — HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and

HomesToLife (HTLM) reported 1H 2026 net revenue of US$198.3M, up 10% YoY, driven by export and retail sales growth. Gross profit rose 14% to US$57.0M, but net income fell 39% to US$6.1M due to foreign exchange losses. Operating cash outflows narrowed to US$8.3M. The company expects stable sales growth for FY2026, maintaining revenue guidance of US$400M–US$420M.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.